Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COMMENTARY
COMMENTARY
- Ex-Health Minister Tamura’s Clout Likely to Grow in Nagatacho
October 14, 2014
- MHLW Has Trick Up Its Sleeve to Skirt 3 Straight Years of “Full-Scale” NHI Price Revisions
October 6, 2014
- Revised PAL to Embrace “Deeper” Safety Measures, Yet Also Escape Clauses to Ease Company Burdens
September 29, 2014
- Series of CRPC Drugs Make Japan Debut, Expanded Indications Key to Success
September 24, 2014
- Picture of Future Regulations on Investigator-Led Clinical Research Emerging
September 9, 2014
- With No Pilot at Helm, Pharma Industry Embroiled in Confusion with Voluntary Funding Disclosures
September 1, 2014
- Wholesalers’ Q1 Earnings Remain Positive, Medical Fee Cut Rule Seen to Boost Accuracy of Financial Results in Sept.
August 25, 2014
- Japanese Drug Makers Working to Increase Pace of Drug Discovery by Optimizing Operations at Research Centers
August 18, 2014
- PMDA Sets Target Review Times for Partial Changes to Generic Approval - A New Way to Underpin Stable Supply
August 4, 2014
- Competition Fuels Personalized Medicine Market, First-Line Positions Eyed for Xalkori, Alecensa
July 28, 2014
- Can New Fast-Track Review System Perk Up Drug Makers’ Development Drive in Japan?
July 7, 2014
- June Reimbursement Listing Could Mark Watershed in Japan Generic Market
July 1, 2014
- Two Reasons MHLW Opposes Yearly NHI Price Revisions, “Annual” Dropped from Gov’t Policy Guidelines
June 17, 2014
- Delicate Balancing Act Required for SGLT-2 Inhibitor Promotions - Safety vs Efficacy
June 16, 2014
- Why Not Make RMPs for Existing Products as Differentiation Strategy?
June 9, 2014
- 2013 Earnings Signal Foreign Drug Makers Losing Steam in Japan
June 2, 2014
- Clinical Research Regulations at Crossroads: Guidelines or Legislation?
May 26, 2014
- Was the Main Paper from VART Study “Practice” for a Grad Student?
May 19, 2014
- Can CROs Become Independent Players? Compliance, Ethics Will Be Major Issues for Growing Industry
April 28, 2014
- Industry Faces Tough Road to Institutionalization of Key Premium, Eligibility Up for Discussion
April 21, 2014
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…